Prognostic significance and dynamic change of plasma macrophage migration inhibitory factor in patients with acute ST-elevation myocardial infarction

Abstract

Supplemental Digital Content is available in the text

Macrophage Migration Inhibitory Factor (MIF)-Based Therapeutic Concepts in Atherosclerosis and Inflammation

“…One strategy might be to specifically target the MIF/CXCR2 interface which is atheropromoting and largely detrimental in the myocardium during an ischaemic insult. Both antibodies and peptide-based compounds such as stabilized derivatives of MIF [47][48][49][50][51][52][53][54][55][56] could potentially qualify as MIF/CXCR2-specific agents. Similarly, inhibitor strategies specifically targeting the MIF/CXCR4 interaction could be envisioned, although great caution would need to be taken to spare the various protective activities of CXCR4 in the atherogenic vasculature and the ischaemic-stressed heart.…”

“…18,19,49,50 Moreover, MIF plasma levels were found to be elevated in a high proportion of ST-elevation myocardial infarction (STEMI) patients, were suggested to be an early marker of acute STEMI, and STEMI patients with high admission MIF level experienced a poorer recovery of cardiac function and worse long-term adverse outcomes. 19,[51][52][53] Moreover, the role of MIF in myocardial ischaemia/reperfusion injury (MI/RI) has become apparent from clinical studies in cardiac surgery patients and mouse models. The cardiac surgery procedure recapitulates the ischaemic and reperfusion stress seen in myocardial infarction patients, but in contrast to the endogenously occurring myocardial infarction pathology in STEMI patients subjected to percutaneous coronary intervention, the onset of inflammation and oxidative injury in cardiac surgical patients is predictable as cardiac surgery with the cardioplegia-induced myocardial arrest, assistance of cardiopulmonary bypass and the following myocardial reperfusion, reproducibly elicits an ischaemia-reperfusion sequelae.…”

Major Adverse Cardiovascular Events: An Inevitable Outcome of ST-elevation myocardial infarction? A Literature Review

“…Among all 75 studies, 62 studies explained percutaneous coronary intervention (PCI) either as the intervention of choice or as a primary intervention inclusive of other management strategies. Coronary angiography was explained as the investigation of choice in four studies [9,[32][33][34].…”

Prognostic role of macrophage migration inhibitory factor in patients with myocardial infarction with ST-segment elevation after percutaneous coronary intervention

“…Установлено, что уровень МИФ был значительно выше у пациентов, которые достигли конечной точки, чем у пациентов с благоприятным течением заболевания, что отвечает более ранним исследованиям [8]. Биомаркер МИФ проявлял защитные функции в отношении пострадавшего при ОИМп ST миокарда, чем, вероятно, и объясняется дополнительная роль уровня МИФ в прогнозе заболевания [9].…”

“…Известно, что по сравнению с тропонином MИФ экспрессируется кардиомиоцитами [11] или иммунными клетками [12,14], может высвобождаться жизнеспособными и «подверженными стрессу» кардиомиоцитами [9] в качестве механизма самосохранения, в то время как тропонин поступает в кровоток из разрушенной клеточной мембраны мертвых клеток [13]. Это дает право утверждать, что биомаркер МИФ играет роль в более тонких патогенетических механизмах нежели тропонин, что подтверждено результатами нашего исследования.…”